Full Press Release Details
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026.
RYTM
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Key Takeaway: Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
Price reaction · baseline $88.38 (2026-06-12 close) · 1 other RYTM headline(s) in the window, move may be shared
day 0 close
+1.5%
day 1
+1.5%
day 3 · peak
+9.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+55%
120-day peak, hindsight
Typical move
3.9%
average across 14 past catalysts
Cash runway
~108 mo
Low dilution risk
Lead asset
RM-131
Phase 1 · Chronic Constipation